New combo therapy aims to keep advanced throat cancer at bay
NCT ID NCT07238569
Summary
This trial is for people with advanced nasopharyngeal cancer (a type of throat cancer) that hasn't fully responded to initial chemotherapy. It will test if adding a chemotherapy pill (capecitabine) to an immunotherapy drug (adebrelimab) for a year after standard treatment is better at preventing the cancer from coming back or spreading than using the immunotherapy drug alone. The main goal is to see which approach gives patients more time without their cancer progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.